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PRELIMINARY RESULTS OF PHASE II TRIAL OF CLOFARABINEWITH PAR-
ENTERAL BUSULFAN (CLO/BU) FOLLOWED BY ALLOGENEIC RELATED
OR UNRELATED DONOR TRANSPLANTATION FOR THE TREATMENT OF
HEMATOLOGIC MALIGNANCIES
Agura, E.1,2, Berryman, R.B1,2, Luis, P.1,2, Estil, V.1,2, Tadic-
Ovcina,M.1,Woelfel, R.1, Fay, J.1,2 1Charles A Sammons Cancer Center,
Baylor University Medical Center, Dallas, TX; 2Texas Oncology P.A.,
Dallas, TX
Background: RIT regimens are now common, but relapse remains
a problem. To address this issue, we proposed and tested a ‘‘mid-in-
tensity’’ conditioning regimen using clofarabine (CLO) with busul-
fan (BU). We hypothesized that this combination would be well
tolerated and offer greater anti-leukemic efficacy than existing RIT
regimens.
Methods:We enrolled 20 patients on this IST, with AML(10), ALL
(1), CLL (1), MDS (2) and MDS-AML (6). 15 patients had prior
therapies. The conditioning was: CLO 40 mg/m2 iv daily x5, BU
3.2 mg/kg iv daily x2, followed by 1 rest day, followed by HSCT.
Donors were matched at A, B, C, DR and DQ using DNA SBT or
mid-res DNA typing. Mismatch# 1 antigen was allowed. GVHD
prophylaxis was Tacrolimus and MTX 5 mg/m2 iv.
Results: Endpoints included toxicity, incidence/severity of
AGVHD, and disease response.
Grade 4 hem toxicity occured in all patients. GCSF was used in
18 of 20 subjects. The median time to recovery of ANC was 15
days (d9 – d17). Donor engraftment (.80% donor chimerism at
d30) occurred in all patients by FISH and/or STR. 2 patients
had hand/foot syndrome (1 Gr. 3, related); 1 respiratory failure
(Gr. 3 possibly related) resolved completely; 1 patient had elevated
ALT/AST (Gr.4, related) which resolved once regimen completed;
other toxicities were #Gr. 2. There were no transplant related
mortalities.
AGVHD occurred in 15 patients within the first 100 days. Of
these, 80% were grade 1-2 and 20% grade 3-4. There were no deaths
attributed to AGVHD following the study regimen.
The disease responses are: 10 (56%) patients, refractory(4), in re-
lapse (1), active disease (5) prior to initiation of CLO/BU, achieved
CR by d30. 7 (39%) patients who were in CR at study entry, remain
so at d30. 2 patients were N/E for disease response at d30. One pa-
tient (w/CLL) acheived CR at d132. 4 (22%) patients relapsed. 9
(45%) patients expired from: cardiac arrest (1, d316); aspergillus
pneumonia (1, d158); TTP (1, d438); AGVHD – post DLI (1,
d175); relapse (4, d222 median); MSOF (1, d91). Of 18 evauable pa-
tients, 10 (55%) remain in remission with a median follow up of 401
days.
Conclusions: CLO/BU is a mid-intensity allo HSCT regimen
with promising antileukemic efficacy that seems to be well toler-
ated without significant cardiac, renal or pulmonary toxicities.
Furthermore, CLO/BU resulted in full donor engraftment by
day 30 in all patients. Enrolment is closed; collection of data is
ongoing.329
EVALUATION OF BUSULFAN’S DOSE-INTENSITY IN PATIENTS UNDERGO-
ING ALLOGENEIC STEM CELL TRANSPLANTATION (ASCT) WITH TWO
DIFFERENT FLUDARABINE/BUSULFAN/ATG (FBA)-BASED REDUCED IN-
TENSITY CONDITIONING (RIC) REGIMENS
Hamadani, M.1, Craig, M.1, Abraham, J.1, Tse, W.1, Cumpston, A.1,
Stotler, C.J.1, Remick, S.C.1, Bunner, P.1, Leadmon, S.1, Elder, P.2,
Hofmeister, C.2, Penza, S.2, Andritsos, L.2, Blum Benson, W.2,
Jr, D.M.2, Devine, S.M.2 1West Virginia University, Morgantown,
WV; 2The Ohio State University, Columbus, OH
We evaluated the effects of busulfan’s dose-intensity in patients
undergoing RIC ASCT at two different transplant centers. Forty-
three patients were conditioned with busulfan (0.8 mg/kg/dose IV
 8 doses), fludarabine (30 mg/m2/day, days -7 to -3), and 6 mg/
kg of ATG (L-FBA), while 23 patients received a ‘more-intense’
RIC with busulfan (130 mg/m2/day IV, days -6 to -3), fludarabine
(40 mg/m2/day, days -6 to -3), and 6 mg/kg of ATG (H-FBA).
Median age was 55 years. 84% (N5 56) had high-risk disease. 19patients (29%) received mismatched allografts. 55 patients (83%)
received grafts from unrelated donors. Baseline characteristics
were well balanced between the two cohorts, except for higher pro-
portion of unrelated donors in L-FBA group (p-value5 0.02). All
patients engrafted neutrophils and platelets (median 17 and 13
days, respectively). There were no graft rejections. Compared to
patients receiving H-FBA, those receiving L-FBA had fewer
CMV reactivations (48% vs. 30%; p-value5 0.15), bacterial infec-
tions (69% vs. 43%; p-value5 0.004) and slightly lower rates of
1-year non-relapse mortality (17% vs. 7%; p-value5 0.19). Com-
pared to L-FBA, H-FBA did not reduce relapse rates (34% vs.
43%; p-value5 0.49). Rate of grade II-IV acute GVHD (30% vs.
52%; p-value5 0.08) favored L-FBA, while incidence rate of
chronic GVHD (40% vs. 40%; p-value5 0.11) were similar. Me-
dian day +90 and +360 chimerism for both groups was 100%. 38
patients (58%) were in CR after ASCT. The median follow-up
of surviving patients is 12 months. Compared to patients receiving
H-FBA, ones receiving L-FBA showed a significantly superior
1-year overall survival (44% vs. 68% p-value5 0.02) and trend
toward improved 1-year progression free survival (33% vs. 60%
p-value5 0.07). Our preliminary, retrospective data suggests that
L-FBA maintains acceptable rates of disease relapse, non-relapse
mortality, full-donor cell chimerism and GVHD control compared
to H-FBA, and may be associated with lower rates of infectious
complications and improved survival.330
INFLUENCE OF COMORBIDITIES ON TRANSPLANT OUTCOMES IN PA-
TIENTS AGED 50 YEARS OR MORE AFTER MYELOABLATIVE CONDITION-
ING INCORPORATING FLUDARABINE, BUSULFAN AND ATG
Elkourashy, S.A.1, Yang, M.1, Turner, R.2, Larratt, L.M.2,
Brown, C.B.1, Bahlis, N.J.1, Savoie, L.M.1, Daly, A.1, Geddes, M.1,
Storek, J.1, Zacarias, N.1, Duggan, P.R.1, Quinlan, D.2, Stewart, D.1,
Russell, J.A.1 1Tom Baker Cancer Centre/Foothills Hospital, Calgary,
AB, Canada; 2Cross Cancer Institute, Edmonton, AB, Canada
Non-myeloablative (NST) and reduced intensity (RIC) regimens
are offered to older patients (pts) and/or those with comorbidities
because the morbidity and mortality attributable to fully myeloabla-
tive conditioning is thought to be unacceptably high. All such pa-
tients receive myeloablative protocols in our program, outcomes
have been analyzed in order to determine whether this practice is jus-
tifiable. Between 1999 and 2008 207 patients (pts) with hematologic
malignancy aged 50–66 years (median 56) received blood cell (87%)
or marrow transplants after conditioning with Flu 50 mg/m2 daily
5 and IV Bu 3.2 mg/kg daily 4. 90 (43%) had additional total body
irradiation (TBI) 200 cGy  2. Graft-versus-host disease (GVHD)
prophylaxis was cyclosporin A, methotrexate and Thymoglobulin
(Genzyme) 4.5 mg/kg total dose. Donors were matched siblings in
125 (60%) mismatched related in 11 (5%), 10/10 matched unrelated
in 54 (26%) and mismatched unrelated in 17(8%). 74 pts (36%) had
low-risk (LR, acute leukemia CR1/CR2, CML CP1) disease. As de-
fined by the HCT-CI scoring system 117 (57%) pts scored 0 (low
HCT-CI), 68 (33%) 1 or 2 (intermediate HCT-CI) and 22 (11%,)
$3 (high HCT-CI). Transplant risk factors were similar between in-
termediate and high HCT-CI groups. As NRM (33% and 33% vs
24% and 48%, p5 ns) and DFS (46% and 37% vs 64% and 43%,
p5 ns) at 1 and 5 years respectively were also similar, outcomes in
these 2 groups were combined for more robust analysis. The propor-
tion of pts with LR disease was higher in those with comorbidities
(intermediate and high HCT-CI) (49% vs 26%, p5 0.0006) than
those without. OS was 56% and 39% vs 74% and 54%
(p5 0.008), DFS 50% and 38% vs 68% and 49% (p5 0.03),
NRM 31% and 39% vs 15% and 19% (p5 0.003) and relapse
26% and 36% vs19% and 39% (p5 ns) respectively at 1 and 5 years.
In 48 AML pts in CR1 & CR2, 27 (56%) with comorbidities, receiv-
ing this protocol with TBI DFS at 5 years was 66%. We conclude
that: 1. Comorbidities influence NRM with this regimen although
cannot confirm that the high HCT-CI group is at higher risk than
the intermediate. 2. Age alone should not be an indication to prefer
a less intense protocol particularly in a condition such as AML where
there is an effect of regimen intensity on relapse. 3. Although NRM
Poster Session II S281with this regimen is high in older patients with comorbidities, formal
comparison with similar patients receiving NST or RIC regimens is
warranted.331
ASSOCIATION BETWEEN THE HEMATOPOIETIC CELL TRANSPLANTA-
TION-SPECIFIC COMORBIDITY INDEX (CIN) AND NON-RELAPSE MOR-
TALITY (NRM) AFTER REDUCED INTENSITY CONDITIONING (RIC)
ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO-SCT) FOR ACUTE
MYELOID LEUKEMIA (AML) IN FIRST COMPLETE REMISSION (CR1)
Mohty, M., Labopin, M., Basara, N., Cornelissen, J., Tabrizi, R.,
Malm, C., Perez-Simon, J.A., Nagler, A., Kroger, N., Rio, B.,
Martino, R., Eder, M., Bilger, K., Bunjes, D.W., Socie, G., Blaise, D.,
Polge, E., Rocha, V. On behalf of the Acute Leukemia Working Party
(ALWP) of EBMT
The adapted Charlson CIn (Sorror-CIn) was useful for predicting
NRM and survival in allo-SCT patients. However, the value of this
CI index is still under considerable debate, since the cohort used by
Sorror et al. (Blood 2005) included a heterogeneous group of pa-
tients. On the other hand, toxicities and NRM prediction is most
likely needed in elderly and medically infirm patients who are in-
creasingly offered RIC allo-SCT. Thus, the current study was de-
signed to test the performance of this CI and its association with
outcomes among a cohort of 345 patients (i) aged .50 y.; (ii) diag-
nosed with a single disease entity, AML in CR1, and (iii) who under-
went a RIC allo-SCT reported to the EBMT registry.
In this series, the median age was 58 y. (range, 50-76). A fludara-
bine-based RIC regimen was used in 64% of patients, while 31% re-
ceived low-dose TBI as part of their RIC, and 6% received other
non-specified RIC regimens. 76% of the patients received allo-
SCT from an HLA-matched sibling donor.
Based on score calculated with HR estimated on the population
studied, 161 patients (47%) had a CIn score of 0, 96 (29%) had a score
of 1, and 49 (14%) had a CI score of 2. 39 patients (11%) had CI
scores of 3 or more. In this cohort, 2 y. overall and LFS rates were
646 3% and 546 3% and the 2 y. relapse and -NRM cumulative in-
cidences (CI) were 326 2%, and 156 2% respectively. The 2 y.
NRM CI according to comorbidities score 0, 1, 2 and 3+ were
96 2%, 156 4%, 186 5% and 316 7%, respectively. In multivar-
iate models (adjusted for age, donor type, use of TBI or not, and cy-
togenetics risk group) comorbidities such as moderate active liver
disease, obesity, prior history of renal dysfunction, and prior history
of severe liver disease were associated with the highest HRs for 2 y.
NRM (varying from 2.11 to 2.76) and 2 y. CI of NRM varying from
22% to 44%, whereas previous solid tumor, diabetes, rheumatologic
abnormalities, moderate pulmonary diseases, cardiac abnormalities
(other than arrhythmia and valve disease) were associated with the
lowest HRs (varying from 0.2 to 1.0) with 2 y. CI of NRM varying
from 5 to 17%.
Results from this study performed in a single disease entity, sug-
gest that the hematopoietic cell transplantation-specific CIn is an in-
formative and useful tool for capturing pre-transplant comorbidities,
and for predicting NRM after RIC allo-SCT for AML in CR1 in
patients aged .50 y. Such index may be used for clinical trials and
patient counselling before RIC allo-SCT.332
A NOVEL REDUCED TOXICITY PREPARATIVE REGIMEN FOR HEMATO-
POIETIC CELL ALLOGRAFTING COMBINING PENTOSTATIN (NIPENT)
AND TARGETED DOSES OF INTRAVENOUS BUSULFAN (BUSULFEX)
WITH OR WITHOUT RITUXIMAB (PB6 R) USING CD4-GUIDED IMMUNE
SUPPRESSION: PRELIMINARY RESULTS OF AN ONGOING PROSPECTIVE
TRIAL
Kharfan-Dabaja, M.A.1, Perkins, J.1, Cortes, R.1, Brand, L.1,
Fernandez, H.F.1, Ochoa-Bayona, J.L.1, Field, T.1, Perez, L.1,
McIsaac, C.1, Maddox, B.1, Ayala, E.1, Komrokji, R.2, Pinilla-
Ibarz, J.2, Sotomayor, E.2, Tomblyn, M.1, Anasetti, C.1 1H. Lee Moffitt
Cancer Center, Tampa, FL; 2H. Lee Moffitt Cancer Center, Tampa, FL
This reduced toxicity regimen evaluates CD4-guided immune
suppression to facilitate early robust CD3 donor engraftment. Itconsists of a pre-conditioning treatment phase with Pentostatin
4 mg/m2 (days -28, -21, -14) if host CD4 counts are .100/uL; and
Rituximab 375 mg/m2 (days -21, -14, -7) in CD20+ lymphoid malig-
nancies. Conditioning phase consists of Pentostatin 4 mg/m2 (days
-4,-3) and two doses of I.V Busulfan (1st dose5 200 mg/m2 (day
-4) and 2nd dose (day-2)5 adjusted for cum. AUC5 16,000 micro-
mol*min/L 610%). Pts with CD20+ disease receive Rituximab
(375 mg/m2 on +1, +8). Primary study endpoint is$ 50% donor chi-
merism by day +28 (67) in CD3 + PB lymphocytes. At time of this
report 25 pts, M/F5 19/6, median age 56 (40-72) years, were evalu-
able. Diagnoses included 8 CLL (1 PR1, 1 CR2, 1 PR2, 5$ PR3), 4
mantle cell (1CR2, 2 PR2, 1 PR3), 4 follicular NHL (1CR2, 1 PR2,
1CR3, 1PR4), 2 Richter’s (1. PR2, 1CR3), 2 AML(1 CR1, 1 PIF), 1
MDS (Persistent), 1 B-PLL (PR2), 1 T-cell NHL-NOS (PR2), 1 T-
PLL (PR1), and 1 Waldestrom’s (PR1). Median (range) CD4 levels/
uL on days -28, -21, -14, -7, and 0 were 368 (27-842), 172 (33-571),
116 (41-277), 130 (43-344) and 34 (9-161), respectively. Median
(range) AUC for 1st, 2nd, and cum. Busulfan dose were 8,374
(6,058-11,124), 9,032 (5,432-13,215), and 17,567 (15,010-21,215),
respectively. All received G-CSF mobilized PBSC from 13 MRD,
7 MUD, 5 MMUD (B Ag5 2; C Ag5 1; DQ Ag5 2). Median
CD34+ dose infused was 9.01 (3.38-10.03) x106/kg cells. GVHD
prophylaxis was TAC-MTX in 21 (84%) and TAC-SIR in 4
(16%). No ATG was administered. Median (range) days to ANC
and PLAT engraftment were 17 (8-28) and 16 (10-33), respectively.
Twelve pts (48%) did not drop PLAT\20 K/uL. Median (range)
donor CD3, CD33 and unsorted BM chimerisms on day 28 (67
days) were 86% (59%-100%), 100% (95%-100%), 95% (90%-
100%), respectively (table 1). Non-relapse mortality at 100 days,
180 days, and at median F/U [269 (39-564) days] were 0%, 4%,
and 12%, respectively. One pt (MDS) died of progression. There
was no evidence of EBV reactivation or PTLD. aGVHD (max grade)
was: 05 4 (16%), I5 9 (36%), II5 9 (36%), III-IV5 3 (12%).
cGVHD by NIH consensus in 21 evaluable pts was: none5 5
(23.8%), mild5 5 (23.8%), mod5 8 (38.1%), and severe5 3
(14.3%). All but 5 pts received Rituximab making it not possible to
comment on its impact on GVHD at this time. PB6R is a safe reg-
imen that ensures early durable donor CD3 engraftment with mini-
mal NRM. Data will be updated at presentation.
Table 1.
Day 286 7 Day 906 7% Donor engraftment
by STR/PCR Median (range) Median (range)CD3 86% (59%-100%) 96% (77%-100%)
CD33 100% (95%-100%) 100% (100%-100%)
Unsorted BM 95% (90%-100%) 96% (78%-100%333
FREQUENCY OF ALLOGENEIC STEM CELL TRANSPLANT (SCT) IN PA-
TIENTS PRESENTING WITH NEWLY-DIAGNOSED AML OR AML AT TIME
OF FIRST SALVAGE THERAPY
Sandhu, R., Petersdorf, S., Sandmaier, B.M., O’Donnell, P., Becker, P.S.,
Deeg, H.J., Appelbaum, F.R., Estey, E.H. Fred Hutchinson Cancer Re-
search Center, Seattle, WA
Allogeneic SCT is widely considered the therapy most likely to
prolong survival in pts with AML in first complete remission
(CR1) or relapse (REL). Questions have arisen regarding the fre-
quency with which the procedure is undertaken in a defined popu-
lation of pts presenting with newly-diagnosed AML and
subsequently followed through REL and after, or in pts presenting
in REL. We first analyzed 26 consecutive pts age\70 who did not
have CBF AML, who were not NPM1+/FLT3-, and who achieved
CR1 with at least 4 months have elapsing from presentation date.
These patients would typically be considered candidates for SCT
in CR1. Eleven of the 26 (42%, 95% CI 23-63%) received SCT
at a median of 3.5 months (range 0.5-9.0) from CR date. Rates
